So today Mesoblast has outlined pricing for their paediatric SR-aGvHD therapy, Ryoncil. A cool US$194,000 per infusion, for a total of 8 infusions. A cool US$1,552,000 per patient.
The contrasts with analyst expectations for Cynata's adult HR-aGvHD therapy, which is estimated to cost US$150,000 per patient (US$100,000 in Europe), or 90% less than what is offered by Mesoblast.
What happens to the Cynata price target of $0.67 if the treatment cost is increased 2x? 3x? 5x? 10x? Are you getting it now?
So today Mesoblast has outlined pricing for their paediatric...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 14285 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |